Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment
| Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment |
| Autore | Dorobantu Maria |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing AG, , 2024 |
| Descrizione fisica | 1 online resource (523 pages) |
| Altri autori (Persone) |
VoicuVictor
GrassiGuido Agabiti-RoseiEnrico ManciaGiuseppe |
| Collana | Updates in Hypertension and Cardiovascular Protection Series |
| ISBN | 3-031-39315-5 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Introduction -- Contents -- Part I: Epidemiology of Hypertension and Hypertensive Heart Disease -- 1: Epidemiological Aspects: Prevalence and Risk of Heart Failure Related to Blood Pressure -- 1.1 The Prevalence and Incidence of Heart Failure (HF) -- 1.1.1 Heart Failure Definition and Classification -- 1.1.2 The Prevalence of Heart Failure -- 1.1.3 The Incidence of Heart Failure -- 1.1.4 Secular Trends in Heart Failure Epidemiology -- 1.1.5 Heart Failure Epidemiology in Middle- and Low-Income Countries -- 1.1.6 Mortality in Heart Failure -- 1.2 The Epidemiology of Hypertension and Heart Failure -- 1.3 Conclusions -- References -- 2: An Update on the Prevalence of Heart Failure -- 2.1 Introduction -- 2.2 Definition of HF and Its Changes -- 2.2.1 Lifetime Risk -- 2.2.2 Prevalence -- 2.3 Heart Failure with a Reduced Versus a Preserved Ejection Fraction -- 2.4 Asymptomatic Left Ventricular Dysfunction (ALVD) -- 2.5 Future Directions -- References -- 3: Heart Failure in Severely Hypertensive Children -- 3.1 Introduction -- 3.2 Severe Hypertension and Heart Failure -- 3.2.1 The Etiology of Severe Hypertension in Children and Adolescents -- 3.2.2 Clinical Presentation -- 3.2.3 Initial Investigations -- 3.2.4 Imaging Studies -- 3.2.5 Mechanisms -- 3.2.6 Treatment -- 3.3 Conclusions -- References -- Part II: Mechanisms of Heart Failure in Arterial Hypertension -- 4: Genetics of Hypertension and Heart Failure -- 4.1 Heritability of Hypertension and Heart Failure -- 4.2 Genetics of Hypertension and Heart Failure -- 4.2.1 Sodium and Intravascular Volume -- 4.2.1.1 Monogenic Hypertension Syndromes -- 4.2.1.2 Monogenic Hypotension Syndromes -- 4.2.1.3 Polygenic Pathways -- 4.2.2 Vascular Mechanisms -- 4.2.3 The Autonomic Nervous System -- 4.2.4 Cardiomyopathies -- 4.2.5 Mendelian Randomization (MR) Studies.
4.2.6 Future Directions -- References -- 5: High Heart Rate: A Predictor of Heart Failure in Healthy Subjects and a Risk Factor for Adverse Outcome in Patients with Heart Failure -- 5.1 Introduction -- 5.2 High Heart Rate As A Risk Factor for the Development of Heart Failure -- 5.2.1 High Heart Rate: A Risk Factor or a Marker of Disease? -- 5.3 Association of High Heart Rate with Adverse Outcomes in Patients with Congestive Heart Failure -- 5.4 The Effect of Heart Rate Reduction in Patients with Heart Failure -- 5.4.1 The Effect of Beta-Blockers in Patients with a Preserved Left Ventricular Function -- 5.4.2 Ivabradine as a Heart Rate-Lowering Agent in Patients with HF -- 5.4.3 Use of Beta-Blockers in HF Patients with Atrial Fibrillation -- 5.5 Summary and Conclusions -- References -- 6: Blood Pressure Variability and Heart Failure: Pathophysiological and Clinical Aspects -- 6.1 Introduction -- 6.2 Relationship of BPV with Preclinical Cardiac Organ Damage -- 6.2.1 Very Short-Term BPV -- 6.2.2 Short-Term BPV -- 6.2.3 Mid-Term BPV -- 6.2.4 Long-Term BPV -- 6.3 Relationship of BPV with Development of Heart Failure -- 6.3.1 Long-Term BPV -- 6.4 The Relationship of BPV with Outcomes in CHF Patients -- 6.4.1 Very Short-Term BPV -- 6.4.2 Short-Term BPV -- 6.4.3 Long-Term BPV -- 6.5 The Paradoxical Prognostic Value of BPV in CHF -- 6.6 Mechanisms of the Relationship Between BPV and CHF -- 6.7 Implications for Treatment -- 6.8 Conclusions -- References -- 7: Hemodynamic Markers in the Progression from Hypertension to Heart Failure -- 7.1 Introduction -- 7.2 LV Remodeling and Hypertrophy -- 7.3 LV End-Diastolic Filling Pressure (Diastolic Function) -- 7.4 LV Deformation -- 7.4.1 Changes in LV Longitudinal Strain in Response to an Increased Afterload -- 7.4.2 Changes in LV Radial Strain in Response to an Increased Afterload. 7.5 The Correlation Network of BP and LV Traits -- 7.6 Assessment of LV and Arterial Elastance -- 7.7 Noninvasive Indexes of LV Myocardial Work from Pressure-Strain Loops -- 7.8 Conclusions -- References -- 8: Sympathetic Activity in Hypertension and Heart Failure -- 8.1 Introduction -- 8.2 Sympathetic Nervous System Activation in Human Hypertension -- 8.2.1 Neural Reflex Mechanisms in the Pathogenesis of Hypertension -- 8.2.2 Interaction Between the Sympathetic Nervous System and the Renin-Angiotensin System -- 8.2.3 Central Neural Activation in Hypertension -- 8.2.4 The Link Between Hypertension and Heart Failure -- 8.3 Sympathetic Nervous System Activation in Heart Failure -- 8.3.1 The Role of the Kidneys in the Pathophysiology of Heart Failure -- 8.3.2 Neural Reflex Mechanisms in the Pathogenesis of Heart Failure -- 8.4 Device-Based Therapeutic Interventions -- 8.4.1 Renal Denervation (RDN) in Hypertension -- 8.4.2 Renal Denervation in Heart Failure -- 8.4.3 Baroreflex Activation Therapy (BAT) in Hypertension -- 8.4.4 Mechanical Endovascular Baroreflex Amplification -- 8.5 Baroreflex Activation Therapy in Heart Failure -- 8.6 Carotid Body Denervation in Hypertension -- 8.7 Carotid Body Denervation in Heart Failure -- 8.8 Future Directions -- References -- 9: Renal and Heart Failure Interrelationship in Hypertension -- 9.1 Introduction -- 9.2 Epidemiology -- 9.3 Mechanisms of Heart Failure and Kidney Dysfunction -- 9.3.1 Hemodynamics -- 9.3.2 Neurohumoral Mechanisms -- 9.3.3 Cardiovascular-Associated Mechanisms -- 9.4 Clinically Relevant Issues -- 9.4.1 Comorbidities -- 9.4.2 Atrial Fibrillation (AF) and Progression in Renal Dysfunction -- 9.4.3 Acute Kidney Injury -- 9.4.4 Anemia -- 9.5 Treatment -- References -- 10: The Role of Uric Acid in Hypertension and Heart Failure. 10.1 The Pathophysiology of Hyperuricemia and Cardiovascular Diseases -- 10.2 The Role of Inflammation in Gout and Cardiovascular Diseases -- 10.3 Hyperuricemia, Hypertension, Heart Failure, and Cardiovascular Disease -- 10.4 The Role of Hyperuricemia in Hypertension and Implications for Heart Failure -- 10.5 The Role of Hyperuricemia in Heart Failure -- 10.6 The Cardiovascular Benefits of Treating Hyperuricemia -- 10.6.1 Xanthine Oxidase Inhibitors -- 10.6.2 Sodium Glucose Cotransporter 2 Inhibitors (SGLT2-I) -- 10.6.3 ARNI -- 10.6.4 Vericiguat -- 10.7 Conclusions -- References -- 11: Myocardial Ischemia: A Link Between Hypertension and Heart Failure -- 11.1 The Link Between Hypertension and Myocardial Ischemia -- 11.2 The Link Between Myocardial Ischemia and Heart Failure -- 11.3 Conclusions -- References -- 12: Role of Endothelial Dysfunction in the Progression from Hypertension to Heart Failure -- 12.1 Endothelial Function -- 12.2 The Cardiometabolic Disease: Focus on the Microcirculatory System -- 12.3 Determinants of Endothelial Dysfunction in Hypertension and Their Role in the Progression to Heart Failure -- 12.3.1 Microvascular Inflammation -- 12.3.2 Cyclooxygenase-2 -- 12.3.3 Mineralocorticoid Receptor -- 12.3.4 Sphingolipid Metabolism and Sortilin -- 12.4 The Progression to HFpEF -- 12.5 Conclusions -- References -- 13: Panendothelitis Due to the SARS COV 2 Infection: Consequences on Hypertension and Heart Failure -- 13.1 Differential Specific Characteristics of SARS CoV 2 and Pathogenic Consequences -- 13.1.1 Proximal Origin, Differential Genomic Characteristics -- 13.1.2 SARS-CoV-2 Virus Cellular Receptor -- 13.1.3 Pathogenesis -- 13.1.4 Pathogenesis Associated with the Five Phases -- 13.2 ACE2, Physiological Functions, Tissue Distribution, and Functional Correlations. 13.2.1 ACE2, the Receptor for SARS-CoV-2 Virus -- 13.2.2 ACE2 Receptor Polymorphism of SARS-CoV-2 and the Correlation with Clinical Forms of Covid-19 -- 13.2.3 Tissue Expression of ACE2 -- 13.3 Vascular Endothelium and Its Functions as a Princeps Target in the Pathogenesis of Covid-19 Disease -- 13.3.1 Panendothelitis: The Pathogenic Basis Covid-19 Disease -- 13.3.2 Relevant Morphofunctional Characteristics of the Vascular Endothelium -- 13.3.3 The Endothelium and the Systemic Endothelial Dysfunction -- 13.3.4 Protection and Functional Restoration of the Endothelium in Covid-19 -- 13.3.5 Pharmacotherapy of Endothelial Dysfunction -- 13.3.6 The Effects of Antihypertensive Drugs on Endothelial Dysfunction and Inflammation in Covid-19 -- 13.3.6.1 The Inflammasome and Pharmacological Inhibitors -- 13.4 SARS-CoV-2 and Cardiovascular Comorbidities. Common Link: Panendothelitis (Systemic Endothelitis) -- 13.4.1 Cardiovascular Consequences of SARS-CoV-2 Interaction with the ACE2 Receptor When There Are Pre-Existing Comorbidities and/or Conditions That Are Favoring This Reaction -- 13.4.2 Myocarditis or the Direct Viral Infection of the Myocardium with Variable Evidence of Inflammation in Covid-19 Disease -- 13.4.3 Prevalence of Hypertension and Other Conditions as Risk Factors for Covid-19 Disease -- 13.4.4 Mechanisms of Cardiovascular Disorders in Covid-19 Disease -- 13.5 General Conclusions -- References -- 14: Pathophysiology of Hypertensive Heart Disease -- 14.1 Introduction -- 14.2 Left Ventricular Hypertrophy -- 14.3 Abnormal Left Ventricular Geometric Patterns -- 14.4 Diastolic Dysfunction -- 14.5 Systolic Dysfunction -- 14.6 Future Directions -- References -- Part III: New Perspectives on Diagnosis of Heart Failure in Hypertensive Patients -- 15: Left Ventricular Diastolic Dysfunction -- 15.1 Introduction. 15.2 Pathophysiology of Diastolic Dysfunction. |
| Record Nr. | UNINA-9910842297403321 |
Dorobantu Maria
|
||
| Cham : , : Springer International Publishing AG, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment / / edited by Maria Dorobantu, Giuseppe Mancia, Guido Grassi, Victor Voicu
| Hypertension and Heart Failure : Epidemiology, Mechanisms and Treatment / / edited by Maria Dorobantu, Giuseppe Mancia, Guido Grassi, Victor Voicu |
| Edizione | [1st ed. 2019.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 |
| Descrizione fisica | 1 online resource (408 pages) |
| Disciplina | 616.13206 |
| Collana | Updates in Hypertension and Cardiovascular Protection |
| Soggetto topico |
Cardiology
Nephrology Vascular surgery Pharmacotherapy Vascular Surgery |
| ISBN | 3-319-93320-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | PART I. EPIDEMIOLOGICAL ASPECTS -- 1 Epidemiological aspects (prevalence, risk of heart failure connected to blood pressure) -- PART II. MECHANISMS OF HEART FAILURE IN ARTERIAL HYPERTENSION -- 2 The genetic background -- 3 Blood pressure load and blood pressure variability -- 4 Hemodynamic mechanisms of heart failure in hypertension -- 5 Neural mechanisms -- 6 Natriuretic peptides -- 7 Renal mechanisms -- 8 Metabolic factors -- 9 Role of central blood pressure and arterial stiffening -- 10 Pathophysiologic mechanisms of heart failure in hypertension: an overview -- PART III. DIAGNOSIS OF HEART FAILURE IN HYPERTENSIVE PATIENTS -- 11 Role of echocardiography -- 12 The additive value of cardiovascular magnetic resonance imaging in hypertensive heart disease -- 13 Biomarkers -- PART IV. COMPLICATIONS OF HYPERTENSIVE HEART DISEASE -- 14 Atrial Fibrilation and other arrhythmias in hypertensive heart disease -- 15 Flash pulmonary edema -- 16 Impact of hypertensive heart disease on cardiovascular events and mortality -- PART V. PREVENTION OF HEART FAILURE IN HYPERTENSION -- 17 Non-Pharmacological Treatment -- 18 Differences and similarities between antihypertensive drugs -- 19 Regression under treatment of left ventricular hypertrophy and other structural alterations -- PART VI. TREATMENT OF HEART FAILURE IN HYPERTENSIVE PATIENTS -- 20 Treatment of Heart Failure In Hypertensive Patients - New drugs -- 21 Treatment of Heart Failure with Preserved Ejection Fraction -- 22 Treatment of acute Heart failure in Hypertensive crisis -- PART VII. INVASIVE APPROACHES -- 23 Carotid baroreceptor stimulation -- 24 Renal nerves ablation -- PART VIII. HYPERTENSION, HEART FAILURE AND GUIDELINES -- 25 Heart failure in hypertensive patients - ready for guidelines? . |
| Record Nr. | UNINA-9910337526203321 |
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
White Coat Hypertension : An Unresolved Diagnostic and Therapeutic Problem / / by Giuseppe Mancia, Guido Grassi, Gianfranco Parati, Alberto Zanchetti
| White Coat Hypertension : An Unresolved Diagnostic and Therapeutic Problem / / by Giuseppe Mancia, Guido Grassi, Gianfranco Parati, Alberto Zanchetti |
| Autore | Mancia Giuseppe |
| Edizione | [1st ed. 2015.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 |
| Descrizione fisica | 1 online resource (153 p.) |
| Disciplina |
610
616.12 616.46 616462 |
| Soggetto topico |
Cardiology
Diabetes |
| ISBN | 3-319-07410-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | 1 Historical Notes -- 2 Definition, Terminology and Prevalence -- 3 Diagnostic Approach to white coat effect and white coat hypertension -- 4 Neurogenic and Non-neurogenic Mechanisms -- 5 Predictive Factors -- 6 White coat hypertension and cardiovascular morbidity and mortality -- 7 White coat hypertension and Target Organ Damage -- 8 White Coat Hypertension, metabolic risk factors, and cardiovascular risk profile -- 9 To Treat or Not To Treat?. |
| Record Nr. | UNINA-9910300183703321 |
|
Mancia Giuseppe
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||